Psychedelic Medicine Coalition

What Psychedelic Medicine Coalition does

Psychedelic Medicine Coalition (PMC) is a Washington, D.C.-based 501(c)(3) nonprofit advocacy organization founded in 2020 by Melissa Lavasani. PMC is dedicated to advancing the research, policy, and responsible integration of psychedelic medicines into U.S. healthcare through federal and state-level advocacy, education, and stakeholder convening. Its core audiences are members of Congress and federal agencies (FDA, VA, SAMHSA, NIH), state legislators, healthcare providers and clinical researchers, and patients, caregivers, and veteran advocates. The organization operates as the only D.C.-based nonpartisan member association focused exclusively on psychedelic medicine policy.

PMC's service portfolio consists of policy advocacy, a national legislation tracker (in partnership with Psychedelic Vote), Congressional Scorecards, a curated peer-reviewed Research Database on psychedelic-assisted therapies, news aggregation, an annual Federal Summit on Psychedelic Medicine held at the National Press Club, and advocacy for specific federal legislation including the Innovative Therapies Centers of Excellence Act (H.R. 2623) and its Senate companion (S. 4031). A subsidiary Psychedelic Medicine Political Action Committee (PMC PAC) supports lawmakers favorable to psychedelic research investment. The organization also maintains international alliances with Psychedelic Industry UK and Psychedelics Canada.

PMC's underlying technology is minimal: a website (psychedelicmedicinecoalition.org), an email newsletter, and basic digital tools to operate the legislation tracker and scorecards. The business model is community-led donation funding, with suggested contribution tiers of $20, $50, $75, $100, $250, $500 and custom/recurring gifts; PMC sells no commercial products and has no disclosed revenue, no parent company, no subsidiaries other than the PAC, and no traditional funding rounds. The organization employs approximately 6 people and is led by Founder/CEO Melissa Lavasani alongside a board that includes former NHL player Daniel Carcillo.

Name

Psychedelic Medicine Coalition

Legal name

Psychedelic Medicine Coalition

Website

https://psychedelicmedicinecoalition.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Psychedelic Medicine Coalition is a Washington, D.C.-based 501(c)(3) nonprofit advocacy organization that educates federal and state lawmakers, regulators, clinicians, and veterans to advance the research, policy, and responsible integration of psychedelic medicines into U.S. healthcare.

Ownership category

akta.pro rank

Product category

Healthcare Policy Advocacy Services

NAICS

Voluntary Health Organizations (813212), Social Advocacy Organizations (8133)

SIC

Services-Health Services (8000)

akta.pro primary industry

Medical Missions & Global Health NGOs (BPAGACAI)

akta.pro secondary industries

Healthcare & Medical Congresses (MPAGAGAF), International & Local Implementing NGOs (HLAJAKAD)

Keywords

• Psychedelic medicine advocacy
• Drug policy reform
• Healthcare policy lobbying
• Veteran mental health
• Federal legislation tracking

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Contributions: As a 501(c)(3) tax-exempt nonprofit organization, PMC generates revenue through charitable donations from individuals, organizations, and supporters. The organization solicits donations via its website with tiered giving options ranging from $20 to $500 and above, with recurring gift options available. Donations are tax-deductible within the guidelines of U.S. law.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Psychedelic Medicine Coalition (PMC) is a Washington, D.C.-based 501(c)(3) nonpartisan nonprofit that conducts federal and state policy advocacy to advance the responsible integration of psychedelic medicines into U.S. healthcare. The organization delivers advocacy through legislative lobbying, congressional and state briefings, public education campaigns, policy analysis, grassroots mobilization via a national legislation tracker, and convenes an annual invite-only Federal Summit on Psychedelic Medicine at the National Press Club.

Product overview

Psychedelic Medicine Coalition is a nonpartisan 501(c)(3) nonprofit advocacy organization, not a traditional product company. Its offerings consist of advocacy programs, policy initiatives, and convening services aimed at advancing psychedelic medicine research and access. The core offerings include federal/state/local advocacy, the Psychedelic Vote legislation tracker, Congressional Scorecards, the Federal Summit on Psychedelic Medicine (annual convening), News & Research publication, and advocacy for the Innovative Therapies Centers of Excellence Act. The organization also maintains an International Alliance Partners network and a subsidiary Psychedelic Medicine Political Action Committee.

Differentiator

Problem solved

Functional benefit

Products and services

• Federal, State, and Local Advocacy Program Direct lobbying, congressional testimony, hearings participation, and legislative drafting support aimed at lawmakers and regulators to create, protect, and promote safe, equitable access to psychedelic medicines.
• Federal Summit on Psychedelic Medicine Annual invite-only national policy convening held at the National Press Club in Washington, D.C., bringing together congressional leaders, federal agency representatives, researchers, healthcare system leaders, and veteran advocates to advance psychedelic medicine policy.
• Psychedelic Vote Legislation Tracker National legislation tracker operated in partnership with Psychedelic Vote that monitors psychedelic-related bills at the federal and state levels, supporting grassroots advocates and the public in policy outreach.
• Congressional Scorecards Rating system that tracks congressional members' positions and voting records on psychedelic medicine-related legislation, providing accountability and transparency for voters and advocates.
• Innovative Therapies Centers of Excellence Act Advocacy Dedicated advocacy campaign supporting H.R. 2623 / Senate Bill S.4031 to establish Centers of Excellence within the Department of Veterans Affairs for research, education, and clinical implementation of psychedelic-assisted treatments including MDMA, psilocybin, ibogaine, 5-MeO-DMT, and ketamine.
• Psychedelic Medicine Research Database Compiled research database featuring peer-reviewed studies on psychedelic-assisted therapies including MDMA, psilocybin, LSD, ibogaine, DMT, and ketamine treatments for conditions such as PTSD, depression, and substance use disorders.
• News & Research Publication Curated news aggregation and research publication covering psychedelic medicine developments, clinical trials, policy updates, and industry news.

Quantifiable outcome

• Initiative 81 (Entheogenic Plant and Fungus Policy Act of 2020) passed with 76% approval — the largest ballot initiative win in Washington DC's history
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Psychedelic Industry UKcoreStrategic or Co-development PartnerPMC co-leads an international alliance with Psychedelic Industry UK to foster relationships, collaborate, and advance psychedelic treatment policy at a global scale. This partnership is part of PMC's broader strategy to build international networks and share policy knowledge across jurisdictions.
• Psychedelics Canada (PsyCan)coreStrategic or Co-development PartnerPMC co-leads an international alliance with Psychedelics Canada (PsyCan) to foster relationships, collaborate, and advance psychedelic treatment policy at a global scale. This partnership extends PMC's reach to Canada, facilitating cross-border policy learning and advocacy coordination.
• Psychedelic VotecoreGTM or Marketing PartnerPMC partners with Psychedelic Vote to operate a national legislation tracker covering psychedelic-related bills. The partnership enables PMC to engage grassroots advocates and the public in policy outreach at both the state and federal levels.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Beckley Foundation: Beckley Foundation is a UK-based nonprofit conducting and funding psychedelic research and policy advocacy globally. Like PMC, it focuses on the intersection of psychedelic science, public education, and policy reform, and operates as a member-supported advocacy organization.
• Drug Policy Alliance: Drug Policy Alliance is a leading U.S. nonprofit that advocates for drug policy reform at federal and state levels, including psychedelics and cannabis. Both organizations share a model of policy advocacy, lobbying, public education, and convening to shift U.S. drug laws.
• Multidisciplinary Association for Psychedelic Studies (MAPS): MAPS is the longest-running nonprofit advocacy and research organization focused on psychedelic medicine, sponsoring clinical trials for MDMA-assisted therapy and lobbying for federal rescheduling. Like PMC, MAPS operates at the intersection of research, advocacy, and policy reform for psychedelic medicines, making it the most directly comparable peer.
• American Psychedelic Practitioners Association: APPA is a membership-based professional association for psychedelic practitioners and clinicians. It is directly comparable to PMC as a membership/advocacy association in the psychedelic medicine space, though it focuses on practitioner standards rather than federal legislation.

Emerging players

• Chacruna Institute: Chacruna Institute is a nonprofit that hosts forums, publishes research, and advocates for responsible psychedelic use and policy reform. It overlaps with PMC on education, advocacy, and convening, but operates more through academic and cultural forums rather than direct federal lobbying.
• Usona Institute: Usona Institute is a nonprofit medical research organization sponsoring psilocybin clinical trials for depression. It overlaps with PMC on advancing psychedelic medicine through research and public education, though Usona focuses on clinical development rather than policy advocacy.
• Veterans Alternative Healing: Veterans Alternative Healing is a nonprofit advocating for veteran access to psychedelic-assisted therapies, mirroring PMC's focus on veteran populations and the Innovative Therapies Centers of Excellence Act. It is a peer in the sub-segment of veteran-focused psychedelic advocacy.
• Psychedelic Alpha: Psychedelic Alpha is a research and media organization covering psychedelic industry, policy, and science. While primarily a research/news organization, it serves an overlapping audience of policymakers, investors, and advocates engaged in psychedelic policy reform, similar to PMC's stakeholder ecosystem.

Broad incumbents

• Compass Pathways: Compass Pathways is a publicly listed mental health care company developing psilocybin therapy for treatment-resistant depression. It is a key industry stakeholder that PMC engages with, and represents the type of commercial player whose interests PMC's federal advocacy work directly affects.

Others

• MAPS PBC: MAPS Public Benefit Corporation is the commercial affiliate of MAPS developing MDMA-assisted therapy through FDA approval. As an adjacent commercial entity, it shares stakeholder audiences with PMC and depends on the same federal policy outcomes PMC advocates for.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/psychedelic-medicine-coalition

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psychedelic Medicine Coalition